2
Announcements
Trials
Browse
Landscape
Status
Available
2
No longer available
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
384
Observational
43
Expanded_access
3
Sponsor
Cancer Type
Myeloid
3
Lymphoid
2
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Gynecologic
1
Conditions
Neoplasms
37
Carcinoma, Non-Small-Cell Lung
34
Multiple Myeloma
32
Recurrence
29
Prostatic Neoplasms
28
Melanoma
21
Leukemia, Myeloid, Acute
21
Breast Neoplasms
18
Precursor Cell Lymphoblastic Leukemia-Lymphoma
15
Glioblastoma
15
Pancreatic Neoplasms
14
Sarcoma
13
Neuroblastoma
13
Lymphoma
13
Glioma
11
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
10
Leukemia
10
Ovarian Neoplasms
9
Lung Neoplasms
9
Colorectal Neoplasms
9
Carcinoma, Hepatocellular
9
Small Cell Lung Carcinoma
8
Lymphoma, Large B-Cell, Diffuse
8
Lambert-Eaton Myasthenic Syndrome
8
Pheochromocytoma
7
Neuroendocrine Tumors
7
Neoplasm Metastasis
7
Lymphoma, Non-Hodgkin
7
Gastrointestinal Stromal Tumors
7
Carcinoma, Renal Cell
7
Interventions
venetoclax
1
selinexor
1
ruxolitinib
1
navitoclax
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Expanded_access
×
Primary Myelofibrosis
×
Clear all
NCT07215832
2026-03-02
KEAP
Karyopharm Therapeutics Inc
Available
NCT04745637
2025-11-18
Managed Access Programs for INC424, Ruxolitinib
Novartis
Available
NCT03592576
2024-05-06
Expanded Access to Navitoclax
AbbVie
No longer available